Krystal Biotech (KRYS) is currently under significant scrutiny as it has remained on the FINRA threshold list for 77 consecutive days. The stock exhibits a short interest of 13.7% of the float. Despite a relatively low borrow fee of 0.3%, the persistent presence on the threshold list indicates that short sellers are maintaining their positions despite the stock's recent price volatility.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.